Apple Watch Faces New US Import Ban and $634 Million Lawsuit Over Blood Oxygen Technology
The US International Trade Commission (ITC) has initiated a new review that could potentially block imports of updated Apple Watch models into the country. This development comes on the heels of a California jury ordering Apple to pay $634 million to Masimo, a medical technology company, over the use of blood oxygen technology in the Apple Watch. According to Reuters, the ITC will examine whether Apple’s redesigned blood oxygen feature still infringes on Masimo’s patents, with the goal of completing the review within six months.
Background and Implications
The dispute centers around the Apple Watch’s blood oxygen feature, which is one of the device’s headline health features. The ITC’s decision could have significant implications for Apple, potentially reshaping how the company sells its latest models in the US. If the ITC finds that Apple’s redesigned feature still infringes on Masimo’s patents, imports of the Series 9 and Ultra 2 watches into the US could be halted. This is not the first time Apple has faced issues with the blood oxygen feature; the company previously pulled blood oxygen readings from some units to satisfy an earlier ban, only to restore an updated version after receiving approval from US Customs.
Consequences for Consumers
The outcome of this case could have direct consequences for consumers who use the Apple Watch for health tracking or are considering upgrading to a newer model. A renewed import block could limit the availability of newer models in the US, particularly specific finishes or bands. Furthermore, Apple has demonstrated a willingness to change or remove blood oxygen readings, which means that advertised features may not remain unchanged for the full life of the device. For buyers who prioritize health data, this case serves as a reminder that the availability of advanced health tools can depend on the outcome of patent battles.
Next Steps and Appeal
For now, updated Apple Watch models remain on sale in the US, and the blood oxygen feature continues to function while regulators and courts navigate the next steps. The ITC expects to conclude its review within six months, which means that any new import limits would likely be implemented on a similar timeline. Apple is appealing the $634 million verdict and has also challenged the original ITC import ruling, while Masimo continues to pursue its own lawsuits on multiple fronts. Consumers who are shopping for an Apple Watch soon should verify which health features are active on the specific model they want and be prepared for potential small software changes as the legal fight continues.
For more information on this developing story, visit Here to stay up-to-date on the latest developments in the Apple Watch import ban and lawsuit.
Image Credit: www.digitaltrends.com